Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
In an interview with CURE, Dr. David A. Taub highlighted Prostate Most cancers Consciousness Month by outlining present therapy choices for sufferers with...
Kimberly (Cary) Demirhan concludes a three-part collection on bringing most cancers analysis to the group setting.This conclusion to a three-part collection on bringing...
